{"id":10203,"date":"2026-07-07T08:37:54","date_gmt":"2026-07-07T13:37:54","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10203"},"modified":"2026-07-07T10:59:27","modified_gmt":"2026-07-07T15:59:27","slug":"catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","title":{"rendered":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>,\u00a0July 7, 2026<\/span><\/strong>\u00a0—\u00a0Catalent<\/a>, the leader in enabling the development and supply of better treatments for patients worldwide, and\u00a0Terap\u00e9utica del nanoscopio<\/a>, a biotechnology company committed to commercializing novel, disease-agnostic, vision-restoring therapies for patients with photoreceptor loss due to retinal degenerations, today announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope’s lead optogenetic gene therapy, MCO-010.<\/p>

Under the expanded partnership, Catalent will provide commercial-compliant packaging and distribution for MCO-010 and has secured the commercial packaging validation program to support Nanoscope’s Biologics License Application (BLA). A rolling submission with the U.S. Food and Drug Administration (FDA) is currently underway.<\/p>

“Catalent is pleased to expand our collaboration with Nanoscope as MCO-010 advances toward potential commercialization,” said Ricky Hopson, Group President, Clinical & Specialty Services and Chief of Staff. “Catalent is committed to supporting Nanoscope at every stage of the journey to bring this innovative therapy to the market and help make Nanoscope’s mission of vision restoration a reality for patients around the globe.”<\/p>

“As we continue to manufacture MCO-010 commercial drug product, having a packaging partner who can scale with us to meet the needs of global commercialization is essential,” said Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope Therapeutics. “Catalent’s expertise and reliability give us confidence as we prepare for the next stage of this journey, and we look forward to continuing this partnership as we work to bring a much-needed treatment option to patients living with retinal degenerative diseases.”<\/p>

MCO-010 is being developed to restore vision in patients with advanced retinal degenerative diseases, including retinitis pigmentosa and Stargardt disease, by reprogramming retinal cells to become light-sensitive. This approach is designed to treat patients with late-stage disease who currently have limited therapeutic options.<\/p>

About Catalent<\/b><\/p>

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture, and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit\u00a0www.catalent.com<\/a>.<\/p>

Acerca de Nanoscope Therapeutics<\/b><\/p>

Terap\u00e9utica del nanoscopio<\/a>\u00a0is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b\/3 multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, as\u00ed como las designaciones Sakigake y hu\u00e9rfana de la PMDA para distrofias retinianas hereditarias (IRD) y las designaciones hu\u00e9rfana de la EMA y la SFDA para IRD. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:<\/b><\/p>

Catalent
media@catalent.com<\/a><\/p>

Nanoscope Therapeutics, Inc
+1 (817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0July 7, 2026\u00a0—\u00a0Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and\u00a0Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease-agnostic, vision-restoring therapies for patients with photoreceptor loss due to retinal degenerations, today announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope’s lead optogenetic gene […]<\/p>\n","protected":false},"author":1,"featured_media":10204,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nCatalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T13:37:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T15:59:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010\",\"datePublished\":\"2026-07-07T13:37:54+00:00\",\"dateModified\":\"2026-07-07T15:59:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\",\"name\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"datePublished\":\"2026-07-07T13:37:54+00:00\",\"dateModified\":\"2026-07-07T15:59:27+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","og_locale":"es_MX","og_type":"article","og_title":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-07-07T13:37:54+00:00","article_modified_time":"2026-07-07T15:59:27+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010","datePublished":"2026-07-07T13:37:54+00:00","dateModified":"2026-07-07T15:59:27+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"},"wordCount":608,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","url":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","name":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","datePublished":"2026-07-07T13:37:54+00:00","dateModified":"2026-07-07T15:59:27+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10203"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10203\/revisions"}],"predecessor-version":[{"id":10211,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10203\/revisions\/10211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10204"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}